• After successful launch of hempSMART in London, MCOA will follow up with additional launch events in Birmingham and Liverpool
• In London, hempSMART sold out its entire promotional inventory, and more than 1,000 people signed up with the company’s associate networking program
• MCOA and joint venture partner Global Hemp Group are in negotiations with cannabinoid extraction companies in Oregon

Marijuana Company of America Inc. (OTCQB: MCOA) is widening its hempSMART subsidiary’s penetration into Europe by planning Q2 2019 prelaunch events in the Netherlands and Germany. MCOA is following up on the successful launch of hempSMART in London, where all promotional inventory was sold and more than 1,000 people joined the company’s associate networking program (http://ibn.fm/YUup4).

MCOA’s subsidiary, hempSMART, will also add to its successful March brand launch in London with additional launch events in Birmingham and Liverpool. In a news release, MCOA CEO Donald Steinberg said, “HempSMART will continue to put in place the proper preparations to launch in additional EU countries moving forward.”

In addition, MCOA, together with partner Global Hemp Group (CSE: GHG) (OTC: GBHPF) (FRA: GHG), is negotiating with several cannabinoid extraction companies in Oregon for the acquisition of the joint venture’s hemp biomass produced at its Scio farm. Samples processed from the 2018 hemp biomass harvest are being prepared for the extraction companies. Hemp biomass is being processed into CBD crude oil, with results from the extraction test batches expected by mid-April (http://ibn.fm/O5Tpb).

The joint venture partners may also work with local farmers in 2019 to grow hemp in Oregon. This would create another potential joint venture opportunity for MCOA and Global Hemp Group.

MCOA conducts product research and development of legal hemp-based consumer products containing CBD under the brand name ‘hempSMART’. Focused on general health and well-being, MCOA also conducts an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD.

For more information, visit the company’s website at www.MarijuanaCompanyofAmerica.com

NOTE TO INVESTORS: The latest news and updates relating to MCOA are available in the company’s newsroom at http://ibn.fm/MCOA

• Black Iron Inc. is focusing on its Shymanivske iron ore project in Ukraine
• The company’s projects are in the heart of Ukraine’s iron ore belt
• Black Iron recently closed the final tranche of a private placement

Based in Toronto, Ontario, Black Iron Inc. (TSX: BKI) (OTC: BKIRF) (GR: BIN) is a Canadian iron ore exploration and development company. Its focus is on advancing to production its 100-percent-owned Shymanivske iron ore project in Krivyi Rih, Ukraine. This project is in a mining-friendly area surrounded by five other operating iron ore mines. Shymanivske is positioned 330 kilometers southeast of Kiev in central Ukraine, the heart of the KrivBass iron ore mining district (http://ibn.fm/wCgrR).

The Shymanivske iron ore project boasts premier infrastructure, including nearby power and rail, and five sea ports. In addition, the project features a skilled workforce from Krivyi Rih, a city with a population of 750,000 that’s located only eight kilometers from the project site (http://ibn.fm/Z6YyV).

The Shymanivske project is expected to produce an ultra-high-grade, 68 percent iron ore concentrate with nominal impurities, including alumina and phosphorus, at a low operating cost of $31 per tonne and capital intensity of less than $95 per tonne of capacity. Black Iron’s plan is to produce high-grade pellet feed. The company’s concentrate could be used to make sinter or highly valued pellets. The concentrate is an ideal source for pellets, because it doesn’t need to be ground finer.

High-grade pellet feed is set to disproportionately increase in price. The price premium is increasing because of environmental consciousness, mainly in China. Since November 2018, iron ore prices have risen by close to 40 percent. Currently, the price of iron ore has reached its highest levels in almost a year (http://ibn.fm/O5y5x).

In addition, a NI 43-101-compliant resource report and engineering studies have been completed for Shymanivske. The NI 43-101-compliant resource contains 646Mt measured & indicated resources at 31.6 percent iron and an additional 188Mt inferred resource at 30.1 percent iron that will be concentrated to approximately 68 percent iron. The resource is defined by roughly 54,000 meters of drilling. Additionally, there is the potential for resource expansion from more drilling at depth.

The Shymanivske iron ore project features strong economics and a favorable tax rate (http://ibn.fm/qaIaA). The project will involve a phased build beginning at 4MTpa and growing to 8MTpa. Using a $62/T selling price produces a pre-tax NPV (net present value) of $2.1 billion at an 8 percent discount rate and a 43 percent IRR (internal rate of return) ($1.7 billion and 36 percent after-tax).

Recently, Black Iron closed the second and final tranche of its earlier announced non-brokered private placement of units (http://ibn.fm/IcRko). The company intends to use the net proceeds of the offering to secure essential land surface rights and further discussions on construction financing, as well as for general working capital purposes.

Black Iron offers investors an intriguing investment opportunity. The company’s mining permit at Shymanivske encompasses 2.56 square kilometers and is valid until 2024. Moreover, the permit is renewable in 20-year increments. With construction at the Shymanivske iron ore mine set to begin in the coming year, Black Iron is on course for major growth.

The technical and scientific contents of this article have been reviewed and approved by Matt Simpson, P.Eng., CEO of Black Iron, who is a Qualified Person as defined by NI 43-101.

For more information, visit the company’s website at www.BlackIron.com

NOTE TO INVESTORS: The latest news and updates relating to BKIRF are available in the company’s newsroom at http://ibn.fm/BKIRF

• Cannabis Strategic Ventures supports entrepreneurial growth in the emerging legal cannabis and ancillary spaces
• The company boasts a portfolio of unique subsidiaries driving growth and opportunities for vertical integration
• The company is developing its NUGS Farm, and developing other hard asset projects is a priority for Cannabis Strategic Ventures

Cannabis Strategic Ventures Inc. (OTC: NUGS) incubates, develops and partners with category leaders within the cannabis space. Through a selective portfolio of companies, NUGS works to support entrepreneurial growth within the fast-emerging legal cannabis sector. Headquartered in Los Angeles, the company offers outsourced personnel solutions that are custom-made for its diverse clientele.

Cannabis Strategic focuses on leading the way in defining industry best practices for innovation, brand development and product quality. Additionally, the company is committed to implementing a strong foundation of operational infrastructure (http://ibn.fm/Fgad9). Cannabis Strategic is accomplishing these goals by way of its various subsidiaries, which include Asher House Wellness, BudHire, Fitamins, Halo Filters, LYXR and Pure Organix.

Asher House Wellness makes Asher House Wellness Oil, an ingestible oil containing a wide variety of premium hemp phytocannabinoids. For pet consumption, these phytocannabinoids originate from hemp plants grown in the United States. The Asher House’s founding team was recently featured on The Ellen DeGeneres Show.

The company’s BudHire subsidiary matches leading candidates to a wide array of cannabis industry jobs. Offering temporary, seasonal and permanent staffing solutions, BudHire also provides sector-specific professional employment organization and human resources consulting services (http://ibn.fm/jN6s6). Cannabis Strategic intends to leverage Worldwide Staffing’s know-how to expand its business operations into the cannabis staffing market.

The company’s Fitamins subsidiary manufactures sports performance products derived from phytocannabinoids, hyaluronic acid and MSM (methylsulfonylmethane). Cannabis Strategic’s Halo Filters subsidiary has developed industry-leading filters made of patent-pending materials. These materials lessen the presence of harmful chemicals and protect lungs.

The company’s LYXR subsidiary produces a line of luxury skin care products derived from hemp CBD (cannabidiol) and other ingredients. The focus of these products is hydration, regeneration and anti-aging. Moreover, the Pure Organix subsidiary concentrates on products that include PureOrganix. This is a line of high-quality cannabis oil concentrates that are organic and compliant with current Good Manufacturing Practices (cGMP) and Food and Drug Administration (FDA) guidelines.

Furthermore, Cannabis Strategic has an initiative to launch substantial cannabis cultivation with its 20 licenses and NUGS Farm, a six-acre cultivation site (http://ibn.fm/c7FzE). The company also plans to partner with a Santa Barbara County cultivation operation that holds approximately 40 commercial cannabis licenses in Southern California.

In a news release, Cannabis Strategic Ventures CEO Simon Yu said, “Establishing the NUGS Farm and securing these licenses are significant milestones for Cannabis Strategic Ventures. We are proud of what we have accomplished at this stage of the company.”

Cannabis Strategic is clearly spearheading innovation in the vibrant cannabis sector. The company is positioned to capitalize in a cannabis marketplace that’s seeing dynamic growth. Forbes recently noted that the legal cannabis industry should experience significant growth in North America and around the world (http://ibn.fm/Q5DMn). The publication predicted that the largest group of cannabis purchasers will be in North America and that spending will increase from $9.2 billion in 2017 to $47.3 billion by 2027.

Cannabis Strategic Ventures offers a compelling opportunity for clients and investors alike. The company has a vision to shape the cannabis industry’s future by focusing on continual advancement in products, places and people. With brands that are category leaders, Cannabis Strategic Ventures continues to foster exponential growth.

For more information, visit the company’s website at www.CannabisStrategic.com

NOTE TO INVESTORS: The latest news and updates relating to NUGS are available in the company’s newsroom at http://ibn.fm/NUGS

• Hemp industry’s growth exhibiting boom trends in wake of the 2018 Farm Bill’s passage, altering regulatory oversight of the plant
• Sugarmade is focusing efforts on supporting the nascent hemp industry with hydroponic growth supplies
• The company has also signed a supply agreement with Kentucky-based private hemp cultivator Hempistry to support Hempistry’s micropropagation work
• Micropropagation helps growers ensure plant quality by cloning “mother” plants that exhibit preferred genetic traits

Hydroponic agriculture supplier Sugarmade Inc. (OTCQB: SGMD) is preparing to significantly expand its operations in the hemp cultivation industry following recent regulatory changes in the agriculture sector and a new agreement with Kentucky-based hemp cultivator Hempistry Inc. to deliver resources for its plant micropropagation work.

Hemp cultivation is beginning to flourish, after decades of federal prohibition in the United States ceased with President Donald Trump’s signing of the 2018 Farm Bill late last year. Limited research cultivation gave way to full-scale agricultural potential for raising hemp crops, creating anticipation for hydroponics specialty product suppliers such as Sugarmade that are functioning as supportive industries for the boom in grower interest.

Sugarmade’s supply contract with Hempistry for the latter’s micropropagation operations is expected to be an ongoing relationship, as Hempistry grows domestically and into the international arena.

Micropropagation is a process that involves cloning or “propagating” new hemp plants from existing “mother” plants that have shown a desirable genetic profile. Much of the hemp cultivated in North America is grown through this propagation process rather than from seed, and the micropropagation process not only ensures exact replicas of the best mother plants but also allows for a very large number of plants to be readied simultaneously, according to the company.

“With at least 42,000 acres of hemp expected to be planted in Kentucky and considering an average plant density per acre of well over 1,000, farmers in Kentucky will need hundreds of millions of clones over the coming years,” Sugarmade CEO Jimmy Chan, who is also a Hempistry director, stated in a news release. “When these numbers are multiplied over the many other hemp cultivation states, it is easy for anyone to see the strong demand scenario that is quickly developing.”

Kentucky found itself in a position of eminence amid the long-running debate over the Farm Bill’s passage, which was championed by Senate Majority Leader Mitch McConnell, the senior congressman from the Bluegrass State. McConnell pushed for the bill’s passage in large measure to ensure that hemp could be legally grown as an agricultural product without Drug Enforcement Administration prohibition (http://ibn.fm/OrSSG) in an effort to revive the state’s flagging flagship industry. The bill’s success and successive agricultural efforts in Kentucky have led the media to begin branding (http://ibn.fm/cEUm7) the state as the ‘Silicon Valley of Hemp’.

Kentucky farming officials have begun to pin their hopes on hemp as an up-and-coming successor to the state’s tobacco industry, which has a long-controversial history because of tobacco’s impact on users’ health.

“We don’t know if industrial hemp will replace tobacco, but we are going to champion it,” Kentucky Commissioner of Agriculture Ryan Quarles told news outlet CNBC (http://ibn.fm/Kz9i4).

According to the commissioner, the number of the state’s applications for hemp cultivation this year is expected to increase about five times from 2018. Hemp growth is on track to top 50,000 acres this year, up from 16,000 acres for last year, according to the report. With the boom in hemp cultivation occurring this planting season, many of the supplies required for successful micropropagation operations are in very short supply, which makes the Hempistry agreement particularly valuable to both companies.

Sugarmade acquired an option last year to invest up to $1 million in the Hempistry operation at a locked-in 2018 valuation. Privately-held Hempistry expects to engage in both direct cultivation and co-op cultivation activities with local farmers this year. Chan noted that Sugarmade has already commenced processing of micropropagation supply orders.

CNBC’s report notes that Hemp Business Journal expects the hemp industry to reach $1.9 billion in revenues by 2022, up 90 percent from about $1 billion in 2018, while a bullish estimate by researcher Brightfield Group forecasts that the hemp-derived CBD-infused product market could reach $22 billion during the same time period.

For more information, visit the company’s website at www.Sugarmade.com

NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://ibn.fm/SUGAR

• SinglePoint recorded a 344 percent increase in sales during 2018, largely due to the acquisition of its DIGS and JAG subsidiaries in 2017
• The revenue growth amounted to a nearly 10-fold increase in profits, to $267,799
• SinglePoint’s most recent asset purchase agreement, solar energy industry marketers Direct Solar and its affiliate, AI Live Transfers, is expected to begin generating revenues for the company this month

Diversified technology company SinglePoint Inc. (OTCQB: SING) has filed its first annual statement with the Securities and Exchange Commission as a fully reporting issuer, highlighting the successes of the company’s merger and acquisition strategy during 2018, as well as its outlook for the coming months.

The report shows that sales increased by 344 percent during the year, leading to a total of more than $1.1 million by year’s end (http://ibn.fm/AGCYj) as the company solidified its financial position.

The company became a fully reporting entity in August 2018.

“Beginning in fiscal year 2014, we made a strategic decision to transition from a technology-based solutions provider to an acquisition and funding development partner… with a focus on acquiring companies that will benefit from the injection of growth capital and technology integration,” SinglePoint stated in the 10-K report. “The Company is looking to tap into markets with exponential growth opportunities such as blockchain, cannabis, sports betting and mobile payments… Our gross profit was $267,799, for the year ended December 31, 2018, compared with $27,814, for the year ended December 31, 2017.” The nearly 10-fold increase in profits was attributable to SinglePoint’s acquisitions in 2017, primarily the company’s DIGS and JAG subsidiaries.

SinglePoint recently announced that it is pinning new revenue hopes on an agreement to acquire Direct Solar and AI Live Transfers — two companies utilizing the Lending Tree model to market products and services to solar power consumers by providing technological resources that consumers can use to comparatively shop for the solar providers that are best suited to their needs (http://ibn.fm/xVeK4). SinglePoint expects to begin realizing profits from the Direct Solar acquisition this month.

Direct Solar’s revenues have recorded an exponential gain during the past year, topping $1.5 million, and a company press release about the agreement states that the companies expect revenues to exceed $8.2 million during the coming year, reaching about $14 million during the year after that, with annual profits of more than $2.8 million forecast after two years.

“We have spent a lot of time and effort to put the Company in a position to turn a profit in the very near future. With the anticipated acquisition of Direct Solar and the explosive growth we are seeing that goal could become a reality. We are excited about the future of SinglePoint and are in a stronger position now than we have ever been,” CEO Greg Lambrecht stated in a news release.

For more information, visit the company’s website at www.SinglePoint.com

NOTE TO INVESTORS: The latest news and updates relating to SING are available in the company’s newsroom at http://ibn.fm/SING

• Lexaria Bioscience is focusing on its pioneering DehydraTECH drug delivery technology
• The company boasts a portfolio of unique products
• Lexaria continues to conduct research regarding DehydraTECH technology for oral nicotine

Based in Kelowna, British Columbia, Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) focuses on technology for the improved delivery of bioactive compounds. Lexaria is the only global company with patents issued for the oral delivery of all cannabinoids. The company has developed and out-licenses its innovative and cost-effective DehydraTECH drug delivery platform. This technology changes the way that edible cannabinoids enter the body. DehydraTECH delivery technology offers a viable and often healthier substitute to other delivery processes for bioactive substances (http://ibn.fm/yih3f).

Lexaria Biosciences’ proprietary technology improves the taste, speed and delivery of bioactive compounds, including nicotine and cannabinoids. DehydraTECH is proven effective in multiple worldwide studies in significantly assisting the quantity of absorption of a range of lipophilic (fat-soluble) bioactive molecules. DehydraTECH also eliminates the strong tastes and odors of lipophilic compounds. Notably, this technology does so without the need for added sugar or sweeteners (http://ibn.fm/BPOdn).

Furthermore, the DehydraTECH drug delivery platform increases bio-absorption by up to 10 times and lessens the time of onset, with effects being felt within 15 to 20 minutes, as compared to 60 to 120 minutes without the platform. In addition, the technology is patent protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids. Patents are also granted for THC (tetrahydrocannabinol), other psychoactive compounds and NSAIDs (nonsteroidal, anti-inflammatory drugs), as well as nicotine and other molecules.

Lexaria Bioscience has partnered with one of the world’s largest tobacco companies to fund the research and development of the DehydraTECH technology for oral nicotine. Through wholly owned subsidiary Lexaria Nicotine LLC, Lexaria is working to propel innovation in oral, reduced-risk nicotine consumer products utilizing DehydraTECH (http://ibn.fm/1JjdR).

Lexaria’s goal is to perform an extensive series of clinical investigations of oral types of nicotine delivery, funded by its partner, using DehydraTECH technology. The DehydraTECH platform has been shown to deliver nicotine to the brain quicker than traditional delivery systems. The technology could potentially apply to the treatment of nervous system diseases, including Alzheimer’s disease. Moreover, DehydraTECH avoids the dangers associated with smoking.

Lexaria also offers a suite of diverse products (http://ibn.fm/Mnu7n). These products include protein energy bars featuring fiber and protein; ViPova exotic teas, delivering cannabidiol in numerous flavors; and coffee. The company also sells TurboCBD capsules. These are high-absorption, full-spectrum hemp oil capsules. The capsules are designed to boost focus and memory while at the same time lessening fatigue and stress. TurboCBD capsules also contain ginseng and gingko.

Lexaria Bioscience is developing a patent family with supporting intellectual property (IP) in the pharmaceutical sector. Lexaria Pharmaceutical Corp. is the company’s wholly owned subsidiary. Lexaria Pharmaceutical has acquired exclusive international rights to Lexaria’s patent portfolio regarding pharmaceutical applications (http://ibn.fm/QNwSp).

Additionally, Lexaria Hemp Co. holds exclusive international rights to the Lexaria Bioscience patent portfolio regarding hemp-based applications. The Lexaria group also includes Lexaria CanPharm Corp., a Canadian entity. Lexaria CanPharm owns exclusive international rights to Lexaria’s IP applicable to psychotropic bioactive molecules, which act upon human CB1 and CB2 receptors in permitted areas.

Lexaria Bioscience is innovating on multiple fronts. The company’s business model offers the potential for considerable ROI, as it involves developing and out-licensing its DehydraTECH platform to third-party partners and distributors for enhanced revenue. Lexaria continues to move forward with its DehydraTECH drug delivery platform and the sale of company-developed and joint venture products.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

• Wildflower Brands Inc. sees annualized revenues exceeding $1 million for online sales
• The company’s diverse brands service customers nationwide, totaling distribution in over 300 stores
• The CBD product market is estimated to grow to $22 billion by 2022 and $75 billion by 2030

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF), a Vancouver-based cannabis company focused on developing and designing branded products in the cannabis sector, intends to become a global wellness leader through its strategic varied brands in the industry.

Wildflower Brands recently achieved more than 300 percent organic growth in online sales since January 2018, seeing annualized revenues exceeding $1 million. This marked the company’s ninth consecutive quarter of increased revenue, primarily due to its direct-to-consumer online store sales. The company’s distribution in other U.S. markets includes over 80 health care and wellness practitioners, totaling distribution in over 300 stores nationwide  (http://ibn.fm/JZaWO).

The company’s multiple brands work in synergy, allowing Wildflower to diversify its reach into the cannabis industry. King Extracts, a California-based company, was acquired in August 2017. Its focus is on cannabis technology and delivery systems, specifically in California. The company offers a discreet, 97mm small rechargeable vaporizer called the King Recharge. Its concentrates are “clean and sophisticated blends made from CO2 extractions” and are “fractionally distilled for clarity and purity… to deliver a robust, full-flavor profile.”

Wildflower Wellness, the eponymous brand of Wildflower Brands, is a CBD wellness company based in Vancouver and focused on establishing a brand reputation for uncompromising quality and trust. Wildflower’s products are available nationwide in more than 300 brick-and-mortar stores as well as online, and the brand is known for its “uncompromising quality and mission to connect people with the healing power of plants.” Wildflower Wellness products include CBD vaporizers, capsules, tinctures, soaps and topicals, all of which are backed by a 100 percent satisfaction guarantee.

Finally, Exclusive, a dispensary of high-quality cannabis products and accessories, serves the Los Angeles, California, area, with licenses to operate end-to-end in the regulated market. The company “enjoys a close association with select hospital oncology departments and community programs.”

These distinct brands enable Wildflower Brands to engage multiple industries, sharing its expertise in CBD-infused products. The lucrative U.S. CBD market is estimated to grow to $22 billion by 2022 (http://ibn.fm/Tfd8w) and $75 billion by 2030 (http://ibn.fm/quGYY).

For more information, visit the company’s website at www.WildflowerBrands.co

NOTE TO INVESTORS: The latest news and updates relating to WLDFF are available in the company’s newsroom at http://ibn.fm/WLDFF

• Data gathered through ShieldSaver’s proprietary license-plate recognition technology is applicable for repairs, maintenance, insurance, purchasing, parts and more
• New ShieldSaver app allows consumers to connect, source and schedule windshield repairs quickly and at reduced cost
• The automotive glass industry was estimated at $12 billion in 2017; it’s expected to grow at a CAGR of 7 percent until 2024

SinglePoint Inc. (OTCQB: SING) continues to bolster its reputation as a diversified tech holding company with operations in multiple industries and verticals with astute acquisitions and investments. Subsidiary ShieldSaver, acquired in 2018, opens SinglePoint’s portfolio to the multibillion-dollar automotive repair and maintenance industry (http://ibn.fm/EsfSC). The significance of ShieldSaver’s proprietary license-plate recognition technology, which gathers data on both cars and consumers, is considerable, since the data has value far beyond the obvious, as a NetworkNewsAudio publication explains (http://ibn.fm/3iYdI).

The most apparent use is to identify when repairs are needed and then approach car owners about getting the work done, but the data also has value to other stakeholders (http://ibn.fm/KOhU5), such as insurance companies, parking-lot owners, parts suppliers and people buying cars, as it can give them a better understanding of both individual vehicles and the bigger picture. Efficient repair and maintenance work can have valuable knock-on effects, according to an NNW editorial (http://ibn.fm/ZXeSE) titled ‘Data and Connectivity Take Center Stage in Changing World of Automobile Technology’.

The automotive glass market exceeded $12 billion in 2017 and is expected to grow at a compound annual growth rate of 7 percent until 2024 (http://ibn.fm/lv0Vy). Increased vehicle production and sales, novel safety regulations and the demand for advanced glass technologies (smart glass, for example) are all projected to contribute to the massive growth (http://ibn.fm/56uqf).

SinglePoint’s new ShieldSaver app (http://ibn.fm/Sl8Z5) allows people to connect to ShieldSaver’s services directly from their phones, so that they can source and schedule windshield repairs quickly and at reduced cost. ShieldSaver has also developed strategic partnerships with some big names within the sector, including Mygrant Glass, Wally Park, LAZ Parking and others.

“With the new application SinglePoint led in developing over the past year, we have started to grab a lot of attention,” Dan Shikiar, founder of ShieldSaver, said in the NNW editorial. “Opportunities have started to pile up after our first showcase – people who see the ShieldSaver platform absolutely love it. We feel this market is underserved and is ripe for new technologies to streamline for customers and providers.”

SinglePoint specializes in the acquisition of small and mid-sized companies that operate in new technological fields. These acquisitions provide opportunities for investment across a wide range of assets, including payment solutions, cannabis brands, blockchain technology developers and more. Through acquisitions into horizontal markets, SinglePoint is building a solid portfolio that ensures a rich and diversified holding base.

For more information, visit the company’s website at www.SinglePoint.com

NOTE TO INVESTORS: The latest news and updates relating to SING are available in the company’s newsroom at http://ibn.fm/SING

• 2018 major milestones included launch of medicinal and recreational sales channels
• Company sold nearly 406 kilograms of premium cannabis, despite having only 20 percent of Kelowna 1 grow rooms operational during Q4 2018
• Flowr optimizes yields, producing premium and ultra-premium cannabis products with a goal of no irradiation, to maximize profitability

The Flowr Corporation (TSX.V: FLWR) (OTC: FLWPF), a Canadian licensed producer of premium cannabis products, recently shared details of several milestones achieved during the fourth quarter of 2018 that included the company’s first recorded revenues, with nearly 260 kilograms of premium cannabis grown in-house during the period, despite only 20 percent of its facility being operational. Flowr Co-CEO Vinay Tolia noted the significance of the sale as he addressed shareholders during an April 4 conference call.

“The fourth quarter of 2018 marked a major milestone for Flowr, as we launched our medicinal and recreational sales channels after receiving our licenses in August 2018, and sold nearly 406 kilograms of premium cannabis, despite having only 20% of our grow rooms in Kelowna 1 operational during the quarter itself,” Tolia said in a news release (http://ibn.fm/eI6Cb).

Flowr’s cultivation facilities, built with proprietary, patent-pending systems, are designed to consistently generate high crop yields of premium and ultra-premium cannabis products. Flowr’s flagship facility, an 84,000-square-foot campus on seven acres in Kelowna, British Columbia, is engineered to meet pharmaceutical industry production standards for cleanliness without resorting to the taste- and smell-killing gamma irradiation that most other licensed producers use to clean their product (http://ibn.fm/Rmyoh).

Flowr currently has 10 grow rooms in Kelowna 1 licensed for use, with eight rooms propagated with plants, and expects to have all 20 grow rooms fully constructed by the end of the third quarter of 2019. Completion of Kelowna 1 should enable the company to begin capitalizing on strategic growth opportunities for medicinal and recreational use, with approximately 10,000 kilograms of capacity for premium cannabis flower on an annualized basis.

“As a global leader in the premium cannabis industry, our design and cultivation expertise along with our superior IP know-how enables us to grow high quality cannabis on a large scale at what we believe will be industry-leading yields,” Tolia emphasized in a news release. “The revenue numbers reflect our ability to grow and process high quality product with only a fraction of our facility and packaging area complete. Once our Kelowna 1 facility is completed in Q3 2019, our operational efficiency will only improve.”

Flowr also plans to expand its product line by selling a selection of its premium, high-quality cannabis in clone and seed form to customers both at home and abroad. Company Co-CEO Tom Flow announced the venture in an earlier news release (http://ibn.fm/yzT78), calling the move “an exciting and potentially very big market for Flowr that is a natural extension of our high-yield, high-quality approach to cultivation.”

“Growing great cannabis starts with great genetics and clean healthy plants, something few companies are able to provide,” Flow stated in the release. “As we ramp up production, we believe Flowr will be able to offer the select cultivars we use to produce our premium cannabis to cultivators globally.”

According to Stratistics MRC, the global cannabis market accounted for $10.39 billion in 2017 sales and is expected to reach $154.82 billion by 2026, growing at a compound annual growth rate of 35 percent during the forecast period. Some of the key factors propelling the market growth are the medicinal properties of cannabis, increasing legalization of cannabis and advances in genetic development and intellectual property related to cannabis (http://ibn.fm/w6eed).

For more information, visit the company’s website at www.Flowr.ca

NOTE TO INVESTORS: The latest news and updates relating to FLPWF are available in the company’s newsroom at http://ibn.fm/FLWPF

• A majority of Canadian cannabis users identified quality and safety as top factors in choosing where to purchase cannabis
• Canada’s Shoppers Drug Mart is now the exclusive direct-to-patient online provider of FlowrRx products
• Flowr grows premium cannabis with a goal of non-irradiation using production methods that are expected to generate high crop yields at low operating costs

Medicinal cannabis patients in Canada are rightly concerned about how cannabis products prescribed by their physicians are produced. According to Canada’s national statistical agency, Statistics Canada, 76 percent of medical cannabis patients responding to the Q4 2018 ‘National Cannabis Survey’ identified quality and safety as the top factors used in their decision-making process when choosing where to fill their prescriptions (http://ibn.fm/yRfzw).

The Flowr Corporation (TSX.V: FLWR) (OTC: FLWPF), a Canadian licensed producer of premium cannabis products, cultivates its cannabis in a purpose-built facility with controlled environments engineered to grow premium cannabis in rooms that meet pharmaceutical industry production standards for cleanliness. Control over cultivation and innovative practices result in a cost-efficient cultivation process. As the company notes, high yields per square foot are key to ensuring low operating costs and profitability.

Flowr aims to avoid irradiating its final product, something that approximately 80 percent of other cannabis companies do, according to Cannabis Tech (http://ibn.fm/gRISH). Flowr’s commitment to delivering a clean cannabis product that meets Health Canada’s strict testing requirements with a goal of no irradiation sets it apart, as CEO Vinay Tolia explained in a podcast (http://ibn.fm/ieuOV), noting that “the plant needs a lot of TLC.”

Medical cannabis patients can now purchase Flowr’s premium FlowrRx products through the Shoppers Drug Mart online medical cannabis platform, as the company recently announced in a news release (http://ibn.fm/juq7F). This direct-to-patient distribution agreement with Shoppers Drug Mart provides medical cannabis patients with several options.

“Flowr’s premium medical cannabis is grown in what we believe is the industry’s most advanced GMP designed cultivation facility. This relationship is testament to our commitment to ultra-high-quality cannabis cultivation and further solidifies Flowr’s role in Canada’s medical cannabis landscape,” Tolia said in the news release.

Canada opened up recreational cannabis to adult users in October 2018 and has since released new regulations governing cannabis-infused edibles and beverages, along with cannabis concentrates, which are set to be legalized in mid-October 2019. According to Stratistics MRC, the global cannabis market accounted for $10.39 billion in 2017 sales and is expected to reach $154.82 billion by 2026, growing at a compound annual growth rate of 35 percent during the forecast period (http://ibn.fm/bpoFd).

For more information, visit the company’s website at www.Flowr.ca

NOTE TO INVESTORS: The latest news and updates relating to FLPWF are available in the company’s newsroom at http://ibn.fm/FLWPF